Home » Stocks » OGN

Organon & Co. (OGN)

Stock Price: $29.53 USD 0.12 (0.41%)
Updated Jun 22, 2021 4:00 PM EDT - Market closed
After-hours: $29.69 +0.16 (0.54%) Jun 22, 7:10 PM
Market Cap 7.48B
Revenue (ttm) 8.10B
Net Income (ttm) n/a
Shares Out 253.52M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 22
Last Price $29.53
Previous Close $29.41
Change ($) 0.12
Change (%) 0.41%
Day's Open 29.25
Day's Range 28.85 - 29.87
Day's Volume 4,218,326
52-Week Range 27.25 - 38.75

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon Announces Filing of Form 10-Q for the quarter ended March 31, 2021

1 day ago - Business Wire

Although spinoffs of well-known organizations have been known to outperform, you'll want to examine OGN stock carefully. The post Motivation Really Matters When It Comes to Organon appeared first on Inv...

5 days ago - InvestorPlace

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon, A Global Women's Healthcare Company, Completes Acquisition of Alydia Health - A Medical Device Company Focused on Postpartum Hemorrhage

6 days ago - Business Wire

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Multimedia news release announcing the launch of Organon, a global healthcare company formed through a spinoff from Merck.

2 weeks ago - Business Wire

LONDON--(BUSINESS WIRE)--Organon (NYSE: OGN) has today launched as the only global health company of its size, with a singular vision: to make a better and healthier every day for every woman. With a ma...

2 weeks ago - Business Wire

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Multimedia news release announcing the launch of Organon, a global healthcare company formed through a spinoff from Merck.

2 weeks ago - Business Wire

NEW YORK, May 27, 2021 /PRNewswire/ -- Organon & Co. (NYSE: OGN) will be added to the S&P 500 prior to the open of trading on Thursday, June 3, replacing HollyFrontier, which will be removed from the S&...

Other stocks mentioned: LCI, MRK, SPGI
3 weeks ago - PRNewsWire

About OGN

Organon & Co., a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio in the United States, Ca... [Read more...]

Industry
Drug Manufacturers-General
Founded
1923
Stock Exchange
NYSE
Ticker Symbol
OGN
Full Company Profile

Financial Performance

In 2020, Organon's revenue was $8.10 billion, a decrease of -15.05% compared to the previous year's $9.53 billion. Earnings were $2.16 billion, a decrease of -32.88%.

Financial Statements